Helix BioMedix, Inc.
HXBM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$739.29K
Close$
$-0.90
127.3% downside
Current Fair Value
127.3% downsideOvervalued by 127.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $739,289.00 |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-2.45 |
| Beta | 1.37 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.34 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Helix BioMedix, Inc.
8 employees
CEO: Robin L. Carmichael
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company was founded in 1988 and is headquartered in Bothell, WA.